Seven years ago, one of Generation Bio’s scientific founders couldn’t convince any top-tier journals to publish his research.
Now, the same company earned itself a presenting spot at this week’s J.P. Morgan Healthcare Conference, after it raised more than $200 million in two years.
Generation Bio is hoping it will be able to create gene therapies for the masses by blending some tried-and-tested methods and targets with a few novel twists. If the approach works, it could open the door to gene therapies for a slew of new conditions and patients.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect